Form 10-K Arcturus Therapeutics For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Arcturus Therapeutics (ARCT) PT Lowered to $65 at Leerink Partners
March 7, 2025 5:47 AM ESTLeerink Partners analyst Lili Nsongo lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $65.00 (from $70.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Today after close, ARCT reported FY24 earnings and provided a pipeline update. In the partnered vaccine... More



